Company Profile

Quantum Dot Corporation
Profile last edited on: 5/29/09      CAGE:       UEI:

Business Identifier: nanocrystal-based DNA detection tools and diagnostic systems.
Year Founded
1998
First Award
2000
Latest Award
2002
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

26118 Research Road
Hayward, CA 94545
   (510) 887-8775
   N/A
   www.qdots.com
Location: Single
Congr. District: 15
County: Alameda

Public Profile

In October 2005, Quantum Dot was acquired by Invitrogen. Quantum Dot Corporation has expertise in semiconductor nanocrystal (QDOT) technology and its applications. Quantum Dot uses quantum dot crystals – cadmium selenide nanoparticles – to develop biological detection applications. The company released its initial Qdot product in 2002, garnering an excellent response from the research and drug development community. One result of Quantum Dot’s partnership with Matsushita has been the release of an optical scanner used for gene expression analysis. The scanner functions intandem with Qbeads, polystyrene balls coated with quantum dots that permit “bar coding” of DNA strands and cellular structures. Quantum Dot develops nanocrystal fluorophores for life science research. The company's products and services employ quantum dot (Qdot) particles, tiny semiconductor crystals that emit light brightly in a range of sharp colors. These nanometer-sized Qdot particles have unique, highly desirable properties that make them a superior detection platform for

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
20-24

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 2 NIH $831,842
Project Title: Sensitive, Multiplexed Analysis of Breast Cancer Markers
2000 1 NIH $107,400
Project Title: Single Target Detection on DNA Microarrays

Key People / Management

  George W Dunbar -- CEO

  Carol C Lou -- President

  Kenneth Barovsky -- IP Counsel

  Robert H Daniels

  Stephen A Empedocles

  Charles Hotz -- VP, Research and Development

  Gayle Kuokka -- CFO

Company News

There are no news available.